Charles V Herst

US Patent:

7713515, May 11, 2010

Filed:

May 26, 2004

Appl. No.:

10/855879

Inventors:

Patrick Englebienne - Zingem, BE
Kenny De Meirleir - Mechelen, BE
Charles Vincent Herst - Oakland CA, US

Assignee:

R.E.D. Laboratories N.V. - Zellik

International Classification:

A61K 49/00

US Classification:

424 91

Abstract:

Methods are provided for diagnosing and/or characterizing disease involving abnormal levels of cellular apoptosis activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a disease involving abnormal levels of cellular apoptosis. The sample is then assayed for the presence of low molecular weight Actin protein fragments. The assay results are used to diagnose the presence of disease involving abnormal levels of cellular apoptosis activity and/or characterize disease involving abnormal levels of cellular apoptosis activity in the subject, e. g. to confirm an initial disease involving abnormal levels of cellular apoptosis diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.

US Patent:

7754707, Jul 13, 2010

Filed:

Jun 30, 2004

Appl. No.:

10/882993

Inventors:

Karim El Bakkouri - Anderlecht, BE
Patrick Englebienne - Zingem, BE
Kenny De Meirleir - Mechelen, BE
Charles Vincent Herst - Oakland CA, US

Assignee:

R.E.D. Laboratories, N.V./S.A. - Zellik

International Classification:

A61K 31/545

US Classification:

514206, 514200, 514202, 514203, 514204

Abstract:

Methods for treating a host suffering from a chronic immune disease, e. g. , MS or CFS, are provided. In practicing the subject methods, an effective amount of an elastase inhibitory agent, e. g. , a β-lactam containing compound, is administered to the host. Also provided are compositions for use in practicing the subject methods.

US Patent:

7759086, Jul 20, 2010

Filed:

Oct 6, 2004

Appl. No.:

11/661888

Inventors:

Patrick Englebienne - Zingem, BE
Kenny De Meirleir - Mechelen, BE
Charles Vincent Herst - Oakland CA, US

Assignee:

R.E.D. Laboratories, N.V. - Zellik

International Classification:

C12Q 1/34

US Classification:

435 18

Abstract:

The present invention relates to methods and kits for the diagnosis and confirmation of Chronic Fatigue Syndrome (CFS) by measuring elastase activity in a patient sample, preferably a PBMC sample. The assays of the invention can also be used to characterize CFS, to determine the disease stage, the disease progression, the efficiency of a therapeutic regime and/or to predict the recurrence of possible attacks. The assays of the invention advantageously allow CFS to be distinguished from other CICIDs like MS or RA.

US Patent:

20050009202, Jan 13, 2005

Filed:

May 13, 2004

Appl. No.:

10/845777

Inventors:

Patrick Englebienne - Zingem, BE
Kenny De Meirleir - Mechelen, BE
Charles Herst - Oakland CA, US

International Classification:

G01N033/564

US Classification:

436506000

Abstract:

Methods and compositions are provided for use in the diagnosis and treatment of a host suffering from a chronic immune disease. In the diagnostic methods of the subject invention, a host derived sample, typically PBMC or a derivative thereof, is assayed for the presence of low molecular weight fragments of RNase L, typically in conjunction with an evaluation of caspase activity. The results of this assay are then employed to diagnose and/or characterize a chronic immune disease in the host. In the treatment methods of the subject invention, an effective amount of agent capable of enhancing RNase L homodimer activity in the host, e.g., in host PBMC, is administered to the host. Also provided are methods for identifying agents having RNase L cleavage-inhibitory activity or RNase L fragment antagonist activity.

US Patent:

6808936, Oct 26, 2004

Filed:

Aug 23, 2000

Appl. No.:

09/645071

Inventors:

Patrick Englebienne - Zingem, BE
Kenny Leo De Meirleir - Mechelen, BE
Charles Vincent Herst - Oakland CA

Assignee:

R.E.D. Laboratories, N.V. - Zellik

International Classification:

G01N 33564

US Classification:

436506, 435 4, 435 71, 435 29

Abstract:

Methods and compositions are provided for use in the diagnosis and treatment of a host suffering from a chronic immune disease. In the diagnostic methods of the subject invention, a host derived sample, typically PBMC or a derivative thereof is assayed for the presence of low molecular weight fragments of RNase L, typically in conjunction with an evaluation of caspase activity. The results of this assay are then employed to diagnose and/or characterize a chronic immune disease in the host. In the treatment methods of the subject invention, an effective amount of agent capable of enhancing RNase L homodimer activity in the host, e. g. , in host PBMC, is administered to the host. Also provided are methods for identifying agents having RNase L cleavage-inhibitory activity or RNase L fragment antagonist activity.

US Patent:

20210292406, Sep 23, 2021

Filed:

Mar 16, 2021

Appl. No.:

17/202770

Inventors:

- Redwood City CA, US
Scott Burkholtz - Redwood City CA, US
Charles V. Herst - Oakland CA, US
Tom Hodge - Redwood City CA, US
Lu Wang - San Jose CA, US

Assignee:

Flow Pharma, Inc. - Redwood City CA

International Classification:

C07K 16/24
G01N 33/68
C07K 16/28
A61K 47/68

Abstract:

An injectable formulation, comprising: poly(lactic-co-glycolic (PLGA) microsphere encapsulating siltuximab, wherein microspheres are sized to release siltuximab over a period of hours, days and weeks, where the biocompatible polymer releases antibody at an absorption rate which is characterized by an absorption rate constant (Ka (h) in the range of (0.001 to 2.048)+/−20%, or +/−10%, or +/−5%. for use and treating human patients with infections. The invention includes treating patients with viral infections of SARS-Cov-2 using siltuximab.

US Patent:

20200276288, Sep 3, 2020

Filed:

Mar 2, 2020

Appl. No.:

16/806664

Inventors:

- Redwood City CA, US
CHARLES V. HERST - Oakland CA, US
LU WANG - San Jose CA, US
SCOTT R. BURKHOLZ - Greer SC, US

Assignee:

FLOW PHARMA, INC. - Redwood City CA

International Classification:

A61K 39/00
G16B 40/00
G06F 17/18
G16B 5/00

Abstract:

A method of making a personalized cancer vaccine is disclosed. The method includes predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. The predicting step can be implemented using artificial intelligence, statistical modeling, or a combination thereof. Particles are created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a biocompatible material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

US Patent:

20200276289, Sep 3, 2020

Filed:

Mar 2, 2020

Appl. No.:

16/806674

Inventors:

- Redwood City CA, US
CHARLES V. HERST - Oakland CA, US
LU WANG - San Jose CA, US
SCOTT R. BURKHOLZ - Greer SC, US
SERBAN I. CIOTIOS - San Jose CA, US

Assignee:

FLOW PHARMA, INC. - Redwood City CA

International Classification:

A61K 39/00
C12Q 1/6886

Abstract:

A personalized cancer vaccine is disclosed. The vaccine is comprised of particles encapsulating neoantigens. The neoantigens are chosen by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and using the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.